HC Wainwright Issues Pessimistic Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Tuesday, July 21st. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of ($6.84) per share for the year, down from their prior forecast of ($6.77). HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.32) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.60) EPS, FY2027 earnings at ($5.35) EPS, FY2028 earnings at ($4.15) EPS, FY2029 earnings at ($2.29) EPS and FY2030 earnings at $0.64 EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals’s quarterly revenue was up 137.7% compared to the same quarter last year.

Several other analysts have also commented on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. JPMorgan Chase & Co. lowered their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. Royal Bank Of Canada raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Truist Financial lifted their price target on shares of Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, The Goldman Sachs Group upped their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $42.78.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $36.05 on Thursday. The company’s 50 day simple moving average is $33.58 and its 200 day simple moving average is $30.56. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The firm has a market capitalization of $2.14 billion, a PE ratio of -4.97 and a beta of 0.54.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Bellevue Group AG boosted its position in shares of Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after purchasing an additional 124,586 shares during the last quarter. State Street Corp boosted its holdings in Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares during the last quarter. Erste Asset Management GmbH grew its stake in Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after purchasing an additional 40,000 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after purchasing an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP increased its holdings in shares of Agios Pharmaceuticals by 6.4% during the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock worth $77,330,000 after acquiring an additional 140,000 shares during the last quarter.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Negative Sentiment: Agios scrapped the tebapivat sickle cell disease program after Phase 2 data failed to show a compelling benefit versus existing options, a setback that weakens a key pipeline opportunity. Article Title
• Negative Sentiment: Multiple reports highlighted the stock’s decline following the decision, with coverage emphasizing that the company is abandoning the sickle cell candidate after lackluster trial results. Article Title
• Negative Sentiment: Investor sentiment is also being dampened by the loss of a potential growth driver in sickle cell disease, even though Agios’ other PK activator, mitapivat, remains under FDA Priority Review with a PDUFA date of November 1, 2026. Article Title

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.